The Raf kinases Raf-1 and B-Raf are upstream activators of the extracellular signal-regulated kinase (ERK)-signaling pathway and therefore participates in many physiological functions in brain, including neuronal survival and synaptic plasticity. Previously, we observed that activation of ERK-1/2, the downstream component of ERK signaling, is significantly reduced in post-mortem brain of suicide victims. The present study was undertaken to further examine whether suicide brain is also associated with abnormalities in upstream molecules in ERK signaling. The study was performed in prefrontal cortex (PFC) and hippocampus obtained from 28 suicide victims and 21 normal controls. mRNA levels of Raf-1, B-Raf, and cyclophilin were measured by quantitative RT-PCR. Protein levels of Raf-1 and B-Raf were determined by Western blot, whereas their catalytic activities were determined by immunoprecipitation and enzymatic assays. It was observed that the catalytic activity of B-Raf was significantly reduced in PFC and hippocampus of suicide subjects. This decrease was associated with a decrease in its protein, but not mRNA, level. On the other hand, catalytic activity, and mRNA and protein levels, of Raf-1 were not altered in post-mortem brain of suicide subjects. The observed changes were not related to confounding variables; however, Raf-1 showed a negative correlation with age. Also, the changes in B-Raf were present in all suicide subjects, irrespective of psychiatric diagnosis. Our results of selective reduction in catalytic activity and expression of B-Raf but not Raf-1 suggest that B-Raf may be playing an important role in altered ERK signaling in brain of suicide subjects, and thus in the pathophysiology of suicide.
Introduction
Mitogen-activated protein/extracellular signal-regulated kinase (ERK) is a family of serine/threonine protein kinases that are critical for several neuronal functions regulated by growth factors/neurotrophins, and their receptors associated with tyrosine kinases. These include neuronal differentiation and survival of neurons during development, as well as survival and adaptive responses of mature neurons including synaptic plasticity and learning and memory. [1] [2] [3] [4] [5] [6] The prerequisite for ERK activation involves the phosphorylation of ERKs in a cascade of events that leads to their subsequent translocation from the cytoplasm to the nucleus, where they regulate gene expression by phosphorylating specific transcription factors, such as Elk-1 and cAMP-response element binding protein. 7 The activation of ERKs involves a cascade of events in which a small GTP-binding protein, Ras, recruits Raf kinases to the plasma membrane. 8 Raf kinases then phosphorylate and activate ERK kinase, or MEK, which in turn phosphorylates and activates ERKs. 9 The sequential nature of this cascade thus provides multiple points at which the responses can be regulated by phosphorylation, which allows tremendous amplification of extracellular signals.
A recent hypothesis proposes that depression and stress, two important factors that contribute to suicidal behavior, are associated with impairments in neural/structural plasticity, neurogenesis, and cellular resilience. [10] [11] [12] [13] Structural abnormalities in brain of affective disorder patients, during stress, and in suicide subjects have been reported. [14] [15] [16] [17] [18] [19] [20] Since synaptogenesis and synaptic remodeling are influenced by neurotrophic factors and their mediated ERK signaling through tyrosine receptor kinases, 21 a number of studies have examined the role of neurotrophins in depression, 22 during stress 23, 24 and in the pathophysiology of suicide; 25 and that BDNF, one of the neurotrophins, may ameliorate depression. 26 In addition, emerging studies suggest a possible role of ERKs in stress and in mood modulation in rat brain. 27, 28 In a previous study, we were the first to show that activation of ERK1 and 2 is significantly reduced in various structures of post-mortem brain of depressed suicide subjects. 29 Our study indicates not only the possibility of impairment in neural/structural plasticity but also that this pathway may be playing a significant role in the pathophysiology of depression and suicide.
Upstream Raf kinases are the key entry point to the ERK-signaling pathway and function as a central switchboard for controlling the signals flowing through the ERKs. Thus, alterations in the regulation of these Raf kinases may alter the functional response of ERKs. Raf kinases are a family of serine/threonine kinases, which include A-Raf, B-Raf, and C-Raf (Raf-1). [30] [31] [32] These Raf kinases are distinguished by their tissue-specific expression pattern 33 and their mechanisms of activation. 34 A number of biochemical and genetic data point to the importance of Raf kinase as an MEK/ERK activator, such that activation of an inducible version of Raf induces the rapid activation of MEK and ERK, as well as of immediate early genes. 7, 35 A recent study showing that electroconvulsive shock activates Raf kinases in rat brain. 36 provides preliminary evidence of the involvement of these kinases in the mechanism of action of antidepressants and possibly in depression. However, so far, there is no direct evidence of the involvement of these kinases in such pathophysiologic events. The present study was undertaken to evaluate the regulation of the Raf kinases that may be critical in causing an altered ERK-mediated functional response in depression/suicide. To achieve this, we determined the activation and expression of various Raf kinases in prefrontal cortex (PFC) and hippocampus obtained from suicide subjects and nonpsychiatric control subjects.
Materials and methods
Subjects; tissue collection, dissection, and storage The study was performed in Brodmann's area 9 and hippocampus obtained from the right hemisphere of suicide subjects (n ¼ 28) and nonpsychiatric control subjects (n ¼ 21), hereafter referred to as normal controls. Brain tissues were obtained from the Brain Collection Program of the Maryland Psychiatric Research Center, Baltimore, MD, USA. After removal from the cranium, the brains were cut into six major pieces (four cerebral cortical lobes, basal gangliadiencephalon, and lower brain stem-cerebellum), rapidly frozen on dry ice, and stored at À701C until dissection. During dissection, the frontal lobes were sliced into 1-1.5 mm thick coronal sections at a temperature between 0 and 101C To keep the samples frozen, the dissections were performed on a metal plate over a container filled with dry ice. The PFC samples were cut out of the coronal sections by a fine microdissecting (Graefe's) knife under a stereomicroscope with low magnification. The dorsomedial PFC (Brodmann's area 9) was taken just dorsal to the frontopolar area including the most polar portion of the superior and partly the middle superior gyrus between the superior and intermediate frontal sulci. In the sections of the dissected cortical area, the gray and white matters were separated and the gray matter was used in this study. The hippocampus was isolated by blunt dissection into the lateral ventricles to demonstrate the hippocampus at the floor of the lateral ventricle. The hippocampus was removed by cutting through the line of the fimbria and includes CA1-4 and dentate gyrus.
All tissues from normal controls and suicide subjects were screened for evidence of neuropathology by experienced neuropathologists at the brain collection program center. The tissues were examined histologically. Fixed sections of PFC were screened with H & E staining and an antibody to glial fibrillary acid protein. The presence of Alzheimer's disease, infarcts, demyelinating diseases, or atrophy (or clinical history of these disorders) disqualified subjects from the study. In addition, in each case, screening for the presence of HIV was carried out in blood samples, and all HIV-positive cases were excluded. Toxicology data were obtained by the analysis of urine and blood samples. pH of the brain was measured in cerebellum in all cases as described by Harrison et al.
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Diagnostic method
At least one family member, after giving written informed consent, underwent an interview based on the Diagnostic Evaluation After Death (DEAD) 38 and the Structured Clinical Interview for the DSM-IV (SCID). 39 The interviews were carried out by a trained psychiatric social worker. Two psychiatrists independently reviewed the write-up from this interview, as well as the SCID that was completed from it, as part of their diagnostic assessment of the case. Diagnoses were made from the data obtained in this interview, medical records from the case, and records obtained from the Medical Examiner's office. The two diagnoses were compared and discrepancies were resolved by means of a consensus conference. Controls were verified as free from mental illnesses using these consensus diagnostic procedures. This study was approved by the IRB of the University of Illinois at Chicago.
B-Raf kinase assay
Brain samples were homogenized on ice with a glassTeflon homogenizer in lysis buffer (50 mM Tris-HCI (pH 7.5), 100 mM NaCl, 1% Triton X-100, 50 mM NaF, 10 mM sodium phosphate, 5 mM EDTA, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM sodium orthovanadate, and 1 mM AEBSF). The homogenates were centrifuged at 14 000 g for 10 min. Protein concentration in the supernatant fraction was determined by the method of Lowry et al. 40 This fraction, containing 300 mg protein, was incubated with anti-B-Raf antibody (BD Transduction Laboratories, San Diego, CA, USA) for 3 h at 41C and precipitated using anti-rabbit IgGcoated magnetic beads (Dynal Biotech, Brown Deer, WI, USA). A preimmune IgG-immunoprecipitated lysate was run in parallel as a negative control. After three washes with lysis buffer, the B-Raf-bound beads were used for the B-Raf kinase assay, was performed according to the procedure provided in the assay kit (Upstate Biotechnology, Lake Placid, New York, USA) and is based on the phosphorylation of myelin basic protein (MBP) by a B-Raf-activated kinase cascade using radioactive ATP as the final phosphate donor. Briefly, assay dilution buffer (20 mM 3-(N-morpholino) propane sulfonic acid (MOPS) (pH 7.2), 25 mM b-glycerol phosphate, 5 mM EGTA, 1 mM Na 3 VO 4 , and 1 mM dithiothreitol) and the magnesium cold ATP cocktail were added in conjunction with 0.4 mg of inactive MEK-1 and 1 mg of inactive glutathione S-transferase-p42 MAP kinase. This mixture was incubated for 30 min at 301C. Additional assay dilution buffer, MBP, and [g 32 P] ATP were added subsequently and incubated for another 10 min at 301C while shaking thoroughly. Of the supernatant, 25ml were spotted onto P81 phosphocellulose paper. After washing three times with 0.75% phosphoric acid and once with acetone for 5 min each, the radioactivity incorporated into the P81 paper was counted using a scintillation counter. Values were calculated by subtracting the activity level obtained in an IgG-immunoprecipitated control (background) from values obtained in the experimental samples.
Raf-1 kinase assay
Tissue lysates were prepared as described above for the B-Raf kinase assay. Raf-1 was immunoprecipitated from tissue lysate using Raf-1 antibody (Santa Cruz Biotechnology) and protein G agarose (Santa Cruz Biotechnology) as described in detail for the Raf-1 kinase assay kit (Upstate Biotechnology, Lake Placid, NY, USA). The total amount of protein used was 450 mg. Raf-1 kinase assay was determined in protein G agarose enzyme immunocomplex using the same assay kit. A preimmune IgG-immunoprecipitated lysate was run in parallel as a negative control. Briefly, the immunoprecipitated tissue samples containing Tris assay dilution buffer (50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA, and 15 mM dithiothreitol), magnesium cold ATP cocktail, 0.4 mg of inactive MEK-1, and 1 mg of inactive p42 MAP kinase were incubated for 30 min at 301C with agitation. Protein G beads were pelleted and the supernatant fraction was used for further assay. Tris assay dilution buffer, MBP, and [g 32 P] ATP were added to the supernatant fraction and incubated for 10 min at 301C with agitation. Of the supernatant, 25 ml were spotted onto P81 phosphocellulose paper. After washing three times with 0.75% phosphoric acid and once with acetone for 5 min each, the radioactivity incorporated into the P81 paper was counted using a scintillation counter. Values were calculated by subtracting the activity level obtained in an IgG-immunoprecipitated control (background) from values obtained in the experimental samples.
Western blot
Western blots were determined in the same tissue fraction in which Raf-1 and B-Raf activity were determined. Equal volumes of samples (100 mg for BRaf and 150 mg for Raf-1) were resolved onto 10% (w/ v) SDS-polyacrylamide gel and blotted on enhanced chemiluminescence (ECL) membrane (Amersham, Arlington Heights, IL, USA). Membranes were incubated with polyclonal antibodies for Raf-1 or B-Raf (BD Biosciences, San Diego, CA, USA) overnight at 41C The dilution for each antibody was as follows: Raf-1 (1:500), B-Raf (1:200). The ECL membranes were then incubated with horseradish-peroxidase-linked secondary antibody (anti-mouse IgG; 1:500) for 5 h at room temperature and exposed to ECL autoradiography film. The same membranes were stripped and reprobed with b-actin (Sigma Chemical Co., St Louis, MO, USA) antibody, was used as a housekeeping protein. The optical densities (OD) of the bands were quantified using the Loats Image Analysis System (Westminster, MD, USA), and the OD of each band was corrected by the OD of the corresponding b-actin band.
mRNA quantitation mRNA quantitation of B-Raf and Raf-1 was determined in total RNA by competitive RT-PCR. The yield of the total RNA was determined by measuring the absorbency of an aliquot of the precipitated stock at a wavelength of 260/280 nm. Samples with a ratio below 1.8 were rejected. The degradation of mRNA was assessed using denaturing agarose gel electrophoresis and evaluating the sharpness of 28S and 18S rRNA bands. None of the samples used in this study showed any sign of degradation.
The quantitation of Raf-1 and B-Raf mRNA was determined using internal standards. We also determined mRNA levels of cyclophilin used as housekeeping gene. Cloning and synthesis of internal standards have been described in our earlier publication. 41 The primer pairs were designed to allow amplification of 426-796 base pairs (bp): forward, 5 the XhoI restriction site, whereas bold and italicized bases indicate the mutation sites. For cyclophilin, the internal standard was prepared by deleting 65 bp (220-320 bp) 5 0 GGT GGC AAG TCC ATC TAT/AAA TGC TGG ACC CAA CAC. Quantitative analyses of Raf-1, B-Raf, and cyclophilin were performed by competitive RT-PCR as described earlier. 41 Decreasing concentrations of Raf-1, B-Raf, or cyclophilin internal standard cRNAs were added to 1 mg of total RNA. The PCR mixture was amplified for 25-30 cycles. Following amplification, aliquots were digested with XhoI (Raf-1 and B-Raf) in triplicate and run by 1.5% agarose gel electrophoresis. For cyclophilin, the PCR product was run directly on gel without digestion. To make sure that amplified sequences of Raf-1, B-Raf, and cyclophilin match with the corresponding sequences reported in GenBank, the PCR products were sequenced using M13 primer.
To quantitate the amount of product corresponding to the reverse-transcribed and amplified mRNA, the ethidium bromide-stained bands were excised and counted. The results were calculated as the counts incorporated into the amplified cRNA standard divided by the counts incorporated into the corresponding mRNA amplification product vs a known amount of internal standard cRNA added to the test sample. The results are expressed as attomoles mRNA/mg total RNA.
Statistical analysis
Data analyses were performed using the SPSS 8.0 (Chicago, IL, USA) statistical software package. All values reported are the mean7the standard deviation (s.d.). The differences in various measures of Raf-1 and B-Raf, age, gender, pH of the brain and postmortem interval (PMI) between suicide subjects and normal controls were analyzed using the independent-sample 't' test. An a level less than 0.05 was considered statistically significant. The relationships between the mRNA and protein levels, as well as catalytic activity of Raf-1 and B-Raf, and PMI, age, and pH of the brain were determined by Pearson's product-moment correlation analysis. The effects of gender on various Raf-1 and B-Raf measures were determined by an independent sample 't' test comparing males and females. Similarly, an independent sample 't' test was used to compare depressed subjects who showed antidepressant toxicity at the time of death with depressed subjects who did not.
Results
The detailed demographic characteristics of suicide victims and normal control subjects are provided in Table 1 . There were 17 males and four females in the control group, and 19 males and nine females in the suicide group. The age range was 21-87 years, whereas the PMI was in the range of 5-32 h. There were no significant differences in age (t ¼ 0.63,
between suicide victims and normal control subjects.
The mean brain pH values of normal controls and suicide victims were 6.0670.3 and 6.1870.4, respectively, which were not different between these groups (t ¼ 1.00, df ¼ 47, P ¼ 0.32).
Raf-1 and B-Raf activity
Comparison analysis of catalytic activities of Raf-1 and B-Raf showed that the activity of B-Raf was higher than that of Raf-1 in both PFC (t ¼ 7.2, df ¼ 40, Po0.001) and hippocampus (t ¼ 17.37, df ¼ 40, Po0.001). Comparison of Raf-1 between the two brain regions showed that Raf-1 activity in PFC was almost double that in hippocampus, which was statistically significant (t ¼ 7.6, df ¼ 40, Po0.001). In contrast, B-Raf activity was significantly higher in hippocampus than PFC (t ¼ 6.8, df ¼ 40, Po0.001).
Comparison analysis between normal controls and suicide subjects showed that the activity of Raf-1 was not different between these two groups either in PFC (Figure 1a) . However, the activity of B-Raf was significantly reduced in both PFC (t ¼ 5.8, df ¼ 47, Po0.001) and hippocampus (t ¼ 6.63, df ¼ 40, Po0.001) of suicide subjects as compared with normal controls (Figure 1b) .
mRNA levels of Raf-1 and B-Raf mRNA levels of Raf-1 and B-Raf were determined in PFC and hippocampus of suicide victims and normal control subjects by quantitative RT-PCR using humanspecific internal standards. Cyclophilin mRNA was determined in these brain areas as a housekeeping gene, and ratios of mRNA of Raf-1 or B-Raf vs cyclophilin mRNA were calculated. Representative gel electrophoreses showing competitive RT-PCR for Raf-1, B-Raf, and cyclophilin in total RNA isolated from PFC of one normal control subject are given in Figure 2a , b and c, respectively, whereas competitive PCR analyses of Raf-1, B-Raf, and cyclophilin are given in Figure 2d , e and f, respectively. It was observed that the amplification products for Raf-1, BRaf, and cyclophilin arise from the mRNA template at 371, 321, and 304 bp, respectively. The digestion products from Raf-1, B-Raf, and cyclophilin arise from cRNA at 188 þ 183; 161 þ 160; and 239 bp, respectively.
As with Raf-1 and B-Raf activities, we observed that mRNA level of B-Raf was higher in both PFC (t ¼ 10.46, df ¼ 40, Po0.001) and hippocampus (t ¼ 23.69, df ¼ 40, Po0.001). Comparison of Raf-1 mRNA levels between PFC and hippocampus showed that Raf-1 mRNA level was significantly higher in PFC than hippocampus (t ¼ 11.4, df ¼ 40, Po0.001).
On the other hand, mRNA level of B-Raf was significantly higher in hippocampus than PFC (t ¼ 8.7, df ¼ 40, Po0.001).
The results of mRNA levels of Raf-1 in PFC and hippocampus of normal controls and suicide subjects are given in Figure 3a . Comparison of normal controls and suicide victims showed that the mRNA level of Raf-1 was not different in PFC (t ¼ 1.23, df ¼ 47, (Figure 3b) .
Comparison analyses of mRNA levels of cyclophilin between normal controls and suicide victims showed almost the same levels in these two groups in both PFC (controls: 776.667112. 
The ratios of Raf-1 or B-Raf mRNA vs cyclophilin mRNA in PFC and hippocampus are given in Figure  3c and d, respectively. Similar to the results expressed not as a ratio, mRNA levels of Raf-1 and B-Raf were not changed when expressed as a ratio to cyclophilin in PFC (Raf-1: t ¼ 1.58, df ¼ 47, P ¼ 0.12; B-Raf: t ¼ 0.91, df ¼ 47, P ¼ 0.37) or hippocampus (Raf-1: t ¼ 0.63, df ¼ 40, P ¼ 0.51; B-Raf: t ¼ 0.60, df ¼ 40, P ¼ 0.55) of in suicide subjects as compared with control subjects.
Protein levels of Raf-1 and B-Raf
The levels of Raf-1 and B-Raf were determined by Western blot using human-specific antibodies. Western blots showing Raf-1 and B-Raf are given in Figure 4a and b, respectively. We observed a single band for Raf-1 at 74 kDa (Figure 4a) . B-Raf antibody showed a major band at 95 kDa (Figure 4b ). At least 10 splice variants of B-Raf have been reported, 42 and we also observed additional bands using this antibody, but these were quite faint and difficult to quantitate. Some reports suggest that 95 kDa is the major band for B-Raf and it is expressed highly in brain. 30 Therefore, we calculated this band. The apparent molecular weight of b-actin was 46 kDa. b-Actin was used as a housekeeping protein. Ratios of OD of the Raf-1 or B-Raf band with that of the b-actin band were calculated.
Initially, we compared the relative distribution of protein levels of Raf-1 and B-Raf within PFC and hippocampus and also between Raf-1 and B-Raf in PFC and hippocampus. It was observed that the protein level of Raf-1 was higher in PFC than hippocampus (t ¼ 11.31, df ¼ 40, Po0.001). In the case of B-Raf, the protein level was higher in hippocampus than PFC (t ¼ 8.87, df ¼ 40, Po0.001).
Comparison between B-Raf and Raf-1 showed that the level of B-Raf was higher than of Raf-1 in both PFC (t ¼ 13.5, df ¼ 40, Po0.001) and hippocampus (t ¼ 25.17, df ¼ 40, Po0.001).
Bar diagrams showing the comparison of Raf-1 and B-Raf in normal controls and suicide subjects are depicted in Figure 4c and (Figure 4c ). On the other hand, the level of B-Raf protein was significantly lower in both PFC (t ¼ 9.3, df ¼ 47, Po001) and hippocampus (t ¼ 5.0, df ¼ 47, Po001) (Figure 4d) .
Correlation between protein level and catalytic activity of B-Raf
To examine whether the decreased catalytic activity of B-Raf was associated with its protein level, we determined the inter-relationships between the decreases in protein level and in catalytic activity of B-Raf. We observed a significant correlation between the protein level of B-Raf and its catalytic activity both in PFC (r ¼ 0.38, P ¼ 0.006) and hippocampus (r ¼ 0.48, Po0.001).
Effects of diagnosis and antidepressant toxicology
To examine whether the differences in catalytic activity and protein levels of B-Raf between suicide subjects and normal controls were related to depression or were present in all suicide victims, we examined the effect of major depression on these measures. For this purpose, we divided the suicide victims into those who were diagnosed with major depression and those who were diagnosed with other psychiatric disorders or had no mental illness. Out of 28 suicide victims, 11 had major depression. In the suicide group with other psychiatric disorders, there were four with adjustment and/or conduct disorders, two with schizoaffective disorder, one with bipolar affective disorder, three with drug/alcohol abuse, one with polysubstance abuse, one with schizophrenia, and three had no diagnosed psychiatric illness; in two suicide victims the diagnosis was not available. Of the suicide group subjects whose hippocampi were analyzed, all the normal controls and suicide victims were similar as described above except for three suicide victims with major depression, two suicide victims whose diagnosis of psychiatric illness was not available, one suicide victim with adjustment disorder, and one suicide victim with polysubstance abuse. One-way ANOVA between normal controls and suicide subjects with major depression or suicide subjects with other psychiatric disorders showed overall significant differences for both protein P ¼ 1.00; catalytic activity: P ¼ 1.00). However, both these groups showed significant differences when compared with normal control subjects in both PFC (normal control vs suicide subjects with major depression-protein levels: Po0.001; catalytic activity: Po0.001; normal controls vs suicide subjects with other psychiatric disorders-protein levels: P ¼ 0.001; catalytic activity: Po0.001) and hippocampus (normal control vs suicide subjects with major depression-protein levels: Po0.001; catalytic activity: P ¼ 0.001; normal controls vs suicide subjects with other psychiatric disorders-protein levels: Po0.001; catalytic activity: Po0.001).
To examine whether the observed changes in catalytic activity and protein levels of B-Raf in the suicide group were related to antidepressant toxicology, we compared the suicide victims who tested positive for antidepressants in the toxicology screen at the time of death (n ¼ 5) and those who did not (n ¼ 23). We did not find significant differences in protein levels (P ¼ 0.39) or in catalytic activity (P ¼ 0.36) of B-Raf in hippocampus or in protein levels (P ¼ 0.94) or in catalytic activity (P ¼ 0.91) of BRaf in PFC between suicide subjects with and without positive antidepressant toxicology screen results.
Effects of confounding variables
The effects of potential confounding variables, namely, age, gender, PMI, or pH of the brain were evaluated with respect to protein levels and catalytic activity of B-Raf, in which we had found differences between normal controls and suicide victims. We found no significant effects of age on protein levels of B-Raf either in PFC (r ¼ 0.01, P ¼ 0.47) or in hippocampus (r ¼ 0.05, P ¼ 0.77). Similarly, age had no significant effects on catalytic activity of B-Raf either in PFC (r ¼ 0.02, P ¼ 0.89) or in hippocampus (r ¼ 0.18, P ¼ 0.24). In addition, we did not find significant effects of PMI on protein levels or catalytic activity of B-Raf either in PFC (protein: r ¼ 0.08, P ¼ 0.59; catalytic activity: r ¼ 0.18, P ¼ 0.22) or in hippocampus (protein: r ¼ 0.13, P ¼ 0.42; catalytic activity: r ¼ 0.11, P ¼ 0.70). Furthermore, no significant effects of pH of the brain were observed on protein levels or catalytic activity of B-Raf either in PFC (protein: r ¼ 0.13, P ¼ 0.38; catalytic activity: r ¼ 0.17, P ¼ 0.25) or in hippocampus (protein: r ¼ 0.03, P ¼ 0.85; catalytic activity: r ¼ 0.14, P ¼ 0.37).
Although we did not find any differences in catalytic activity, or in mRNA or protein levels, of Raf-1 between normal controls and suicide subjects, we observed a significant negative correlation between age and catalytic activity in both PFC and hippocampus of normal controls and suicide subjects when analyzed separately (normal controls: PFC, r ¼ À0.35, P ¼ 0.02; hippocampus, r ¼ À0.31, P ¼ 0.01; suicide subjects: PFC, r ¼ À0.37, P ¼ 0.05; hippocampus, r ¼ À0.61, P ¼ 0.003).
There were 17 males and four females in the control group and 19 males and nine females in the suicide group. Comparison studies showed no significant dCPT; aliquots were digested by XhoI and electrophoresed on 1.5% agarose gel. Cyclophilin cRNA did not require digestion with restriction enzyme. The higher molecular size band corresponds to the amplification product arising from the mRNA, whereas the lower bands arise from cRNA generated from the internal standard digested by XhoI. Data derived from the agarose gels are plotted as the counts incorporated into the amplified cRNA standard divided by the counts incorporated into the corresponding mRNA amplification product vs the known amount of internal standard cRNA added to the test sample. The point of equivalence represents the amount of Raf-1 (d) B-Raf (e) or cyclophilin (f) mRNA. differences in any of the measures between males and females in protein levels or catalytic activity of B-Raf either in PFC (protein: t ¼ 1.08, df ¼ 19, P ¼ 0.08; catalytic activity: 
Correlation between B-RAF and phosphorylated ERK-1/2
In a previous study, we determined ERK1/2-mediated phosphorylation in PFC and hippocampus of a subset of suicide subjects (n ¼ 11) and normal controls (n ¼ 11), 29 which were also included in this study. We had reported then a significant decrease in ERKmediated phosphorylation in suicide subjects as compared with normal controls. In the present study, we examined whether the previously observed decreased ERK-mediated phosphorylation in suicide subjects was correlated with the currently observed decrease in catalytic activity and in mRNA and protein expression of B-Raf. Interestingly, there is significant correlation between phosphorylated ERK-1/2 and B-Raf measures of catalytic activity (PFC: r ¼ 0.92, P ¼ 0.003; hippocampus: r ¼ 0.94, P ¼ 0.002), mRNA (PFC: r ¼ 0.85, P ¼ 0.015; hippocampus: r ¼ 0.89, P ¼ 0.007), and protein (PFC: r ¼ 0.83, P ¼ 0.02; hippocampus: r ¼ 0.90, P ¼ 0.01).
Discussion
Raf kinases are specific modulators of ERK/MAP kinase signaling. Raf propagates signals by activating the dual-specific kinase MEK. All the three Raf kinases, that is, A-Raf, B-Raf, and Raf-1, share a high degree of sequence similarity. 33, 43 Despite their homology, studies have shown that transcripts of the raf gene exhibit strikingly different expression patterns. A-Raf is present in urogenital tissues and is barely detectable in the nervous system. 33 On the other hand, B-Raf transcripts are present in high levels in brain and cerebrum. 33, 43 Raf-1 gene expression has been detected in all cell lines and tissues examined, with highest levels in brain although mRNA signal for Raf-1 in the brain is much weaker than that of B-Raf. 33 More recently, Morice et al. 44 have shown that at the cellular level, both Raf-1 and B-Raf immunostaining is mostly localized in neurons. They also found that both these proteins are localized not only within the same brain areas but also within the same cells in rat brain; however, the intensities of the immunostaining were different, depending upon the brain structure. In the present study, we observed the presence of both Raf-1 and B-Raf in human postmortem brain; however, the pattern of expression was different in PFC than in hippocampus. In comparison with B-Raf, the mRNA level of Raf-1 was much lower in both PFC and hippocampus. This is quite consistent with the report of Storm et al., 33 who found lower mRNA expression of Raf-1 than the B-Raf in mouse brain. Comparison of mRNA expression levels of Raf-1 between PFC and hippocampus showed that the level of Raf-1 was lower in hippocampus than PFC. However, in the case of B-Raf, the mRNA expression level was higher in hippocampus than PFC. A similar pattern of expression was found for protein levels of both Raf-1 and B-Raf in PFC and hippocampus. Consistent with its mRNA and protein levels, the activity of Raf-1 in both PFC and hippocampus was weaker than that of B-Raf. Our protein expression studies are somewhat similar to those reported by Morice et al., 44 who found that immunolabeling of B-Raf (B98 kDa band) was higher in hippocampus than cortex. However, contrary to our results, they found similar levels of Raf-1 expression in both PFC and hippocampus. As with the expression pattern, the activity of B-Raf was higher in hippocampus than PFC, whereas Raf-1 activity was lower in hippocampus than PFC. Ours is the first study comparing the protein levels, catalytic activity, and mRNA expression of Raf-1 and B-Raf in human brain, and our results suggest that the activity of these kinases depends upon their expression pattern.
Comparison of Raf-1 and B-Raf between normal controls and suicide subjects revealed that there were no significant differences in mRNA or protein levels of Raf-1 between suicide subjects and normal controls either in PFC or hippocampus. The activity of Raf-1 was also unchanged in PFC and hippocampus of suicide subjects. One interesting observation was that only the activity, but not mRNA or protein levels, of Raf-1 was negatively correlated with age in both brain areas, which suggests an age-dependent decline in activity of this kinase.
On the other hand, as in the case of Raf-1, the mRNA level of B-Raf was not altered in PFC or hippocampus of suicide subjects; however, the immunolabeling of the 95 kDa protein was significantly lower in suicide subjects as compared with normal controls. The decrease in B-Raf protein level occurred in both PFC and hippocampus, although the magnitude of the decrease was greater in PFC than in hippocampus. Similarly, the B-Raf kinase assay showed decreased catalytic activity in both PFC and hippocampus of suicide subjects, and again the magnitude of the decrease was greater in PFC than hipocampus. The B-Raf measures in PFC and hippocampus were not correlated with age, PMI, pH of the brain, or gender. Our results thus demonstrate decreases in a specific isoform of Raf kinase, that is B-Raf, and these decreases were present in both PFC and hippocampus of suicide subjects.
The observation of a decrease in only B-Raf, but not Raf-1 is of interest. Raf-1 and B-Raf proteins are differentially regulated and may differ in their ability to activate the MAP kinase system. It has been shown that maximal activation of Raf-1 is produced by synergistic signals from Ras and activated tyrosine kinases. Ras-GTP translocates Raf-1 to the membrane, where it becomes phosphorylated on tyrosine residues 340 and 341 by membrane-bound tyrosine kinases. 45 These investigators further showed that BRaf, by contrast, is strongly activated by Ras alone and is not activated by Src, which suggests that B-Raf merely requires signals that activate Ras-GTP, whereas activation of Raf-1 requires Ras-GTP together with signals that lead to its tyrosine phosphorylation. 46 Interestingly, B-Raf has been identified as the major MEK activator in neuronal cell types even though Raf-1 is expressed in these cells.
47-49 Also, the concept of differential activation of ERK signaling by B-Raf and Raf-1 is supported by the observation that B-Raf exhibited a sustained kinase activity towards MEK, unlike Raf-1, in response to nerve growth factor, 50, 51 which suggests that B-Raf might be necessary to achieve the level of ERK activity required for mediating the survival effects of neurotrophic factors. 52 This sustained kinase activity is critical for cell proliferation or the differentiating response. 53 More interestingly, it has been shown that although both Raf-1 and B-Raf are present in brain, only B-Raf was found to be an activator of MEK in bovine brain. 48, 54 Another major difference in the regulation of Raf-1 and B-Raf is that although both Raf-1 and B-Raf interact with Rap-1, a GTPase of the Ras family that activates the ERK pathway through cAMP in neuronal cells (REF), only B-Raf is activated by Rap-1. 34, 55 This is supported by a study by Dugan et al., 56 who showed that only neuronal cells expressing B-Raf had increased phospho-MAPK in response to cAMP. Interestingly, in a preliminary study, we observed an altered level of Rap-1 and its activation in post-mortem brain of depressed suicide subjects. 57 Furthermore, we observed reduced activation of ERK1/2 in post-mortem brain of suicide subjects 29 and that this decrease was significantly correlated with catalytic activity, mRNA and protein levels of B-Raf. It is quite possible that the pathway mediated by Rap-1/B-Raf/MEK/ERK may specifically be altered in brain of suicide subjects.
The mechanism of decreased levels of B-Raf in post-mortem brain of suicide subjects is not clear at the present time; however, it does not appear to be related at the trasncriptional level since no change was observed in its mRNA level. Also B-Raf is activated by its targeting to the plasma membrane from the cytosol through an association with Ras protein. 8 Although we did not determine the translocation of B-Raf from cytosol, the overall decrease in BRaf protein rules out the possibility of translocation. On the other hand, a decrease in B-Raf activation could be due to the decrease in protein levels of B-Raf. Other mechanisms may also play a role in the decreased activation of B-Raf. For example, B-Raf is mainly regulated by binding to the Ras family of proteins, and it has been shown that binding of Ras-GTP alone suffices to activate B-Raf. 58, 59 In neuronal cells, cAMP activates ERK signaling through a Ras family protein, Rap-1, by activating B-Raf. This happens through PKA, a major enzyme in cAMP signaling, and through Epac, which is directly activated by cAMP. [60] [61] [62] [63] [64] At this level, the B-Raf/Raf-1/MEK/ERK pathways crosstalk to each other. It is quite possible that decreased activation of B-Raf could be due to decreased levels/activity of PKA, Rap-1, or decreased levels of cAMP. Interestingly, we observed that [ 3 H]cAMP binding and PKA activity are decreased in post-mortem brain of depressed suicide subjects. 65 Decrease in PKA activity has also been reported in depressed patients by other investigators. [66] [67] [68] Moreover, we have found decreased expression of Rap-1 in post-mortem brain of these subjects. 57 A number of studies suggest that subjects with affective disorders show morphological changes in brain, including atrophy of neurons and reduction in volumes of PFC and hippocampus. [69] [70] [71] [72] Several postmortem brain studies also suggest reductions in cell number, and density and size of cortical and hippocampal neurons. 16, 17, 19, 73, 74 Stress, a major factor in suicidal behavior, also causes atrophy and loss of neurons. Altered brain structures in brain of suicide subjects have also been demonstrated. 14, 16 In addition, an emerging hypothesis suggests that mood disorders may be associated with an inability to make appropriate adaptive responses to environmental stimuli due to an alteration in neuroplasticity. [11] [12] [13] Since the B-Raf/ERK pathway is activated by neurotrophins and has been shown to regulate differentiation, survival, and structural and functional plasticity of neurons by modulating gene expression and activity-dependent neuronal functions, 3, 5, 75 a role of this pathway has been postulated in the pathophysiology of depression and in the mechamisms of action of psychoactive drugs. In fact, decreased ERK signaling in depressed rats, 76 and in post-mortem brain of suicide subjects has been demonstrated (Dwivedi et al., 2001 ). Antidepressants 77 and mood-stabilizing drugs 28 also activate the ERK pathway. Very interestingly, using knockout mice, Wiese et al. 78 demonstrated that ERK activation is compromised only in B-Raf À/À , 7, 8 but not in Raf-1 À/À 79,80 mice. They also showed that BRaf À/À neurons failed to survive in response to a range of neurotrophic factors, including brain-derived neurotrophic factor, glial-derived neurotrophic factor, and nerve growth factor, whereas Raf-1 À/À mice behaved similarly to wild-type mice, suggesting the importance of B-Raf in neuronal survival.
Our finding of the selectively decreased activation of B-Raf, but not of Raf-1, in post-mortem brain of suicide subjects therefore may be of critical importance and offer a new insight into the pathophysiology of suicide, namely, that B-Raf may be involved in mechanism by which the ERK pathway may be regulated in suicidal behavior.
